Pfizer and Ranbaxy petition Supreme Court in Lipitor
Drugmakers accused of a pay-for-delay scheme have asked the US Supreme Court to review an appellate court’s decision that held plaintiffs do not need to calculate patent litigation costs to allege that a drugmaker cut an illegal deal with a generic competitor.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10